Dyadic International price to sales ratio DYAI

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 3.8×
7-year median: 16.1×
Against its 7-year history: 14th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.1× to 170×
Peer median: 1.1×

Dyadic International's price to sales ratio is 3.8× as of Oct 23, 2026.

That is below its 7-year median of 16.1×, lower than on 86% of days in the last 7 years.

Over that time it ranged from 0.1× in Dec 2022 to 170× in Jun 2020.

The median for 7 healthcare stocks of a similar size is 1.1×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.8×	3.8×	12.1×
2025	10.3×	6.5×	16.2×
2024	17.2×	9.9×	28.3×
2023	15.7×	0.1×	20.8×
2022	0.1×	0.1×	48.2×
2021	52.1×	39.1×	110×
2020	87.5×	56.3×	170×
2019	74.3×	73.0×	86.9×

Against its peers

Companies in Healthcare nearest Dyadic International's size, closest first, today.

Company	Price to sales ratio
DYAIDyadic International	3.8×
NEPHNephros	1.9×
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
Peer median	1.1×

Where Dyadic International ranks

#18of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Dyadic International

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.